AIDS 2022
Fostemsavir Data Looking Bright for Heavily Treatment-Experienced Adults With MDR HIV
After 240 weeks, fostemsavir helped HTE adults with MDR HIV-1 infection achieve durable virologic responses, ...
AUGUST 3, 2022
Bringing Equity to PrEP Use in the United States
Programs that promote and distribute PrEP for HIV should be based on equity, rather than equality, according to ...
AUGUST 3, 2022
Progress in HIV Slowed During Pandemic, But Leaders Working to Regain It
There is no doubt the strides made in controlling the HIV pandemic lost ground because of COVID-19, leaders said at ...
AUGUST 3, 2022
Biktarvy Shows Durable Viral Suppression After 5 Years
Five-year cumulative data from two trials of Biktarvy demonstrated high rates of viral suppression that were ...
AUGUST 3, 2022
TAF- or TDF-Backbone? Both Appear Efficacious for HIV/HBV Co-Infection
A regimen for treating people with HIV and HBC coinfection with a TAF backbone has similar efficacy with one that ...
JULY 29, 2022
